Bard CFO Todd Schermerhorn to retire
This article was originally published in Clinica
Executive Summary
CR Bard's chief financial officer Todd Schermerhorn has announced plans to retire, after 26 years with the company. He will continue to serve as CFO during a transition period expected to last until the end of this month, while his successor is elected. Mr Schermerhorn joined Bard in 1985 as a financial analyst, and held various financial positions until he was promoted to CFO in April 2003 (www.clinica.co.uk, 7 March 2003). The news of his retirement comes soon after Murray Hill, New Jersey-based Bard reported a disappointing second quarter, making a net loss of $47.8m after incurring litigation charges related to its recalled hernia products (www.clinica.co.uk, 25 July 2011). The company recorded 8% year-on-year revenue growth, at $725m, but was hampered by challenging conditions in its domestic market, where sales were up just 3%.
You may also be interested in...
What are the hottest innovations from Israel?
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
EuroPCR: St Jude and Philips talk up rival intravascular imaging techs
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
EuroPCR: Medtronic's drug-coated balloon keeps rising
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.